Abstract
Rats treated chronically with the dopamine D2/D3 receptor agonist quinpirole develop locomotor sensitization and exhibit compulsive checking of specific places in an open-field arena, a behavioral profile that may represent an animal model of obsessive-compulsive disorder. However, it is not known how compulsive checking develops across quinpirole injections nor whether checking behavior possesses a particular temporal structure. Male rats received quinpirole (0.5mg/kg, twice weekly x 10) or an equivalent regimen of saline and were placed in a large open field for 55 min where their behavior was digitally tracked for subsequent analysis of checking behavior using existing and newly developed computer software. Results showed that the measures of compulsive checking did not follow a singular profile across injections: some remained constant and others changed monotonically reaching their near-maximum levels after about 5-7 quinpirole injections. Moreover, results showed that checking behavior was organized into bouts of checking, with the number of bouts, as well as the rate of checking within a bout, increasing across injections to reach near maximal levels after about 5-7 administrations of quinpirole. Finally, quinpirole-trea...Continue Reading
References
Sep 1, 1989·Behavioural Brain Research·D Eilam, I Golani
Jan 1, 1993·Psychopharmacology·B A MattinglyG Lovell
Jun 1, 1994·Psychopharmacology·H SzechtmanD Eilam
Aug 1, 1994·Pharmacology, Biochemistry, and Behavior·H SzechtmanR M Sullivan
Dec 17, 1997·Psychopharmacology·K K SzumlinskiH Szechtman
Oct 21, 1998·Journal of Theoretical Biology·B J TolkampI Kyriazakis
Mar 8, 1999·Animal Behaviour·B J Tolkamp, I Kyriazakis
Feb 1, 1992·Behavioural Pharmacology·P. WillnerR. Muscat
Sep 22, 2001·Physiology & Behavior·A J SpinkL P Noldus
Sep 22, 2001·Neuroscience and Biobehavioral Reviews·D Drai, I Golani
Dec 12, 2001·Journal of Theoretical Biology·M P YeatesI Kyriazakis
Jan 5, 2002·Behavioral Neuroscience·A Ben-PaziD Eilam
Feb 2, 2002·Biological Psychiatry·Yousef TizabiHenry Szechtman
Jan 13, 2004·Neurotoxicity Research·Ryszard BrusJohn P Kostrzewa
Feb 6, 2004·Psychological Review·Henry Szechtman, Erik Woody
Feb 6, 2004·Journal of Neuroscience Methods·Itay HenYoav Benjamini
Oct 21, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Melissa L PerreaultHenry Szechtman
Citations
Oct 26, 2006·Neurotoxicity Research·H Szechtman, E Z Woody
Jul 11, 2007·Psychopharmacology·Melissa L PerreaultJane A Foster
Jan 29, 2013·Psychopharmacology·Mark C TucciHenry Szechtman
Aug 22, 2009·Behavioural Pharmacology·Gregory T Collins, James H Woods
Apr 1, 2014·Psychopharmacology·Mark C TucciHenry Szechtman
Jun 2, 2012·Expert Opinion on Drug Discovery·Kurt Leroy Hoffman
Feb 3, 2011·Neuroscience·B M GuW H Meck
Dec 3, 2014·Behavioural Brain Research·Mark C TucciHenry Szechtman
Feb 9, 2012·Behavioural Brain Research·Kurt L Hoffman, Rafael I Rueda Morales
Nov 27, 2014·Behavioural Pharmacology·Javier Ballester GonzálezHenry Szechtman
Dec 15, 2010·Journal of Psychopharmacology·Ria de HaasHerman G M Westenberg
Dec 2, 2017·Behavioural Pharmacology·Tony D JungHenry Szechtman
Oct 28, 2017·Evolutionary Psychology : an International Journal of Evolutionary Approaches to Psychology and Behavior·Michael J Frederick, Sarah E Cocuzzo
Jul 16, 2008·Behavioural Pharmacology·Anna DvorkinBryan Kolb
Aug 25, 2010·The European Journal of Neuroscience·Anna DvorkinHenry Szechtman
Jun 18, 2014·The European Journal of Neuroscience·Mark C TucciHenry Szechtman
Dec 13, 2019·Pharmacological Reviews·Henry SzechtmanKurt Leroy Hoffman
Mar 7, 2020·Frontiers in Pharmacology·Angélica Del Pilar EscobarJosé Antonio Fuentealba
Mar 25, 2020·Neurotoxicity Research·Mahdi AbounooriMotahareh Rouhi Ardeshiri
May 23, 2017·The International Journal of Neuropsychopharmacology·Angélica P EscobarMaría E Andrés
Jun 27, 2015·Journal of Neurochemistry·Angélica P EscobarMaría E Andrés